Tranexamic acid for prevention of bleeding at caesarean sectio

Not Applicable

• Conditions: Surgery; bleeding at caesarean section

• Registration Number: PACTR201706002304422
• Lead Sponsor: federal teaching hospital abakaliki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-05-20
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 120

Inclusion Criteria

1. Parturients with singleton pregnancy at 37-42 weeks¿ gestational age
2. Patient on admission for elective caesarean section
3. patients without contraindication to tranexamic acid
4. patient who have signed the informed consent

Exclusion Criteria

1. Women who have known allergy to tranexamic acid
2. Women with prior history of thromboembolism
3. Women with bleeding disorders
4. Patients with renal disease
5. Patients with liver pathology
6. Patients with chronic hypertension
7. Patients with preeclampsia/eclampsia
8. Women with antepartum haemorrhage
9. Patients with varicose veins at increased risk of deep vein thrombosis
10. Patients who do not consent to the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Estimated blood loss at elective Caesarean section

Secondary Outcome Measures

Name	Time	Method
Excessive blood at Caesarean section loss defined as blood loss > 1000ml;Change in haematocrit after Caesarean section ;The need for additional uterotonics to control bleeding;The need for blood transfusion during or after the surgery;any maternal side effects